Inhibikase Therapeutics Stock Current Valuation
| IKT Stock | USD 2.76 0.16 5.48% |
Valuation analysis of Inhibikase Therapeutics helps investors to measure Inhibikase Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Inhibikase Therapeutics' Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.09 in 2024, despite the fact that Enterprise Value is likely to grow to (1.9 M). Fundamental drivers impacting Inhibikase Therapeutics' valuation include:
Price Book 26.456 | Enterprise Value 193.1 M | Enterprise Value Ebitda 0.3409 | Price Sales 2.5 K | Enterprise Value Revenue 2.748 |
Undervalued
Today
Please note that Inhibikase Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Inhibikase Therapeutics is based on 3 months time horizon. Increasing Inhibikase Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Inhibikase Therapeutics' intrinsic value may or may not be the same as its current market price of 2.76, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.76 | Real 8.83 | Target 27.0 | Hype 2.93 | Naive 3.41 |
The intrinsic value of Inhibikase Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Inhibikase Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Inhibikase Therapeutics helps investors to forecast how Inhibikase stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inhibikase Therapeutics more accurately as focusing exclusively on Inhibikase Therapeutics' fundamentals will not take into account other important factors: Inhibikase Therapeutics Company Current Valuation Analysis
Inhibikase Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Inhibikase Therapeutics Current Valuation | 193.1 M |
Most of Inhibikase Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibikase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inhibikase Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Inhibikase Therapeutics is extremely important. It helps to project a fair market value of Inhibikase Stock properly, considering its historical fundamentals such as Current Valuation. Since Inhibikase Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibikase Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibikase Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Inhibikase Therapeutics has a Current Valuation of 193.1 M. This is 98.66% lower than that of the Biotechnology sector and 95.84% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.84% higher than that of the company.
Inhibikase Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibikase Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inhibikase Therapeutics could also be used in its relative valuation, which is a method of valuing Inhibikase Therapeutics by comparing valuation metrics of similar companies.Inhibikase Therapeutics is currently under evaluation in current valuation category among its peers.
Inhibikase Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inhibikase Therapeutics from analyzing Inhibikase Therapeutics' financial statements. These drivers represent accounts that assess Inhibikase Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inhibikase Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 102.5M | 55.7M | (13.7M) | (1.8M) | (2.0M) | (1.9M) |
Inhibikase Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibikase Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibikase Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Inhibikase Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (238.85) % | ||||
| Current Valuation | 193.1 M | ||||
| Shares Outstanding | 67.19 M | ||||
| Shares Owned By Insiders | 10.46 % | ||||
| Shares Owned By Institutions | 11.62 % | ||||
| Number Of Shares Shorted | 305.66 K | ||||
| Price To Book | 26.46 X | ||||
| Price To Sales | 2,466 X | ||||
| Revenue | 260.5 K | ||||
| Gross Profit | (8.26 M) | ||||
| EBITDA | (19.91 M) | ||||
| Net Income | (19.03 M) | ||||
| Cash And Equivalents | 32.21 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 622 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.56 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 196.2 M | ||||
| Total Asset | 14.51 M | ||||
| Retained Earnings | (66.9 M) | ||||
| Working Capital | 10.77 M | ||||
| Net Asset | 14.51 M |
About Inhibikase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibikase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.